Navidea Biopharmaceutica (Israel) Financial Diagnostics

NAVB -- Israel Stock  

ILS 73.10  4.90  6.28%

Navidea Biopharmaceuticals diagnostics interface makes it easy to digest most current publicly released information about Navidea Biopharmaceutica as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Navidea Biopharmaceutica price relationship with some important fundamental indicators such as market cap and management efficiency.

Navidea Biopharmaceutica Note

About 35.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 197.2. Navidea Biopharmaceuticals recorded loss per share of 0.09. This company had not issued any dividends in recent years. Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio. Navidea Biopharmaceutica is traded on Tel Aviv Stock Exchange in Israel. To find out more about NAVIDEA BIOPHAR contact Ricardo Gonzalez at 614-793-7500 or learn more at http://www.navidea.com.

Navidea Biopharmaceutica Alerts

Navidea Biopharmaceutica is not yet fully synchronised with the market data
Navidea Biopharmaceutica generates negative expected return over the last 30 days
Navidea Biopharmaceutica has high historical volatility and very poor performance
Navidea Biopharmaceutica has accumulated S2.2 Million in debt which can lead to volatile earnings
The company reported revenue of 1.44M. Net Loss for the year was (16.88M) with profit before overhead, payroll, taxes, and interest of 1.81M.

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 163.82M.

Management Efficiency

Navidea Biopharmaceuticals has return on total asset (ROA) of (42.64) % which means that it has lost $42.64 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (167.76) % meaning that it generated substantial loss on money invested by shareholders.

Navidea Biopharmaceutica Technical and Predictive Indicators

Did you try this?

Run Transaction History Now

   

Transaction History

View history of all your transactions and understand their impact on performance
All  Next Launch Transaction History

Also Currentnly Active

Purchased over 50 shares of
few hours ago
Traded for 56.845
Purchased over 20 shares of
few hours ago
Traded for 141.97
Purchased over 50 shares of
few hours ago
Traded for 56.845
Please see also Stocks Correlation. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Search macroaxis.com